Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

National Report Calls On Government To Negotiate With Manufacturers To Lower Drug Costs

By Meagan Parrish | December 1, 2017

A recent report from the National Academy of Sciences is urging the U.S. government to make major changes in the pharmaceutical market to lower the price of prescription drugs.

The report, called “Making Medicine Affordable: A National Imperative,” was written by 17 expert doctors, lawyers and economists, who derided the government and the pharma industry for its inaction on the issue.

Among its recommendations, the panel said that the government should use its purchasing power to directly negotiate with manufacturers over drug costs for patients using programs like Medicare.

The panel’s other suggestions included:

  • More government intervention in attempts by manufacturers to delay the release of generics or biosimilars.
  • Denying tax deductions for direct advertising to consumers.
  • Increased transparency from drugmakers and insurers on how pharmaceuticals are priced.
  • Setting a $5,000 cap on the amount of out-of-pocket costs Medicare patients must spend each year.
  • Stopping tax and financial incentives for drug development for rare diseases from being used for “widely sold drugs.”
  • Tighter restrictions on visits from pharma sales reps to hospitals and clinics.

According to a report in the Los Angeles Times, the industry’s top lobbying group, the Pharmaceutical Research and Manufacturers of America (PhRMA), criticized the report for rehashing ideas that are outdated and that would “undermine the competitive market that is holding medicine cost growth to the slowest rate in years.”

President Donald Trump has publicly promised to tackle the issue on numerous occasions, and the administration’s nominee to take over the Department of Health and Human Services has vowed to make it a top priority. But so far, the current administration has yet to enact any measures that directly target drug prices. And while many Democrats have embraced proposals such as the ones outlined in the 201-page report, most congressional Republicans remain opposed to such measures.

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards